Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. cut its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,355 shares of the company’s stock after selling 13,601 shares during the period. Fox Run Management L.L.C.’s holdings in Syndax Pharmaceuticals were worth $216,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Assenagon Asset Management S.A. grew its stake in Syndax Pharmaceuticals by 343.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after purchasing an additional 1,598,428 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth approximately $15,150,000. Sphera Funds Management LTD. increased its stake in shares of Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock worth $19,921,000 after buying an additional 212,799 shares during the last quarter. Franklin Resources Inc. raised its holdings in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after acquiring an additional 208,043 shares in the last quarter. Finally, State Street Corp boosted its stake in Syndax Pharmaceuticals by 4.1% during the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after acquiring an additional 148,491 shares during the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Keith A. Goldan sold 3,777 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This represents a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock valued at $336,087 in the last quarter. Corporate insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, March 20th. Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, Citigroup lowered their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Trading Down 2.8 %

Shares of Syndax Pharmaceuticals stock opened at $13.18 on Friday. Syndax Pharmaceuticals, Inc. has a twelve month low of $12.06 and a twelve month high of $25.07. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.63 and a beta of 0.92. The business’s 50 day simple moving average is $14.30 and its 200-day simple moving average is $15.90.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).